Progress Analysis of Top 7 Cancer Indications, Including Players, Drugs, Clinical Progress and Pitfalls.DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c50146) has announced the addition of Top 7 Cancer Indications - Therapeutic & Competitive Insights to their offering. With our 750 page report entitled "Top 7 Cancer Indications - Therapeutic & Competitive Insights" we present one of the largest reports published evaluating therapeutic and competitive insights in the anti-cancer arena. The report is structured according to according to prep. 1. As stated or indicated by; on the authority of: according to historians. 2. In keeping with: according to instructions. 3. the top 7 cancer indications: Breast cancer, Colon/colorectal cancer, Leukemia leukemia (l  kē`mēə), cancerous disorder of the blood-forming tissues (bone marrow, lymphatics, liver, spleen) characterized by excessive production of immature or mature , Lung cancer lung cancer, cancer that originates in the tissues of the lungs. Lung cancer is the leading cause of cancer death in the United States in both men and women. Like other cancers, lung cancer occurs after repeated insults to the genetic material of the cell. , Lymphoma, Melanoma melanoma: see skin cancer. melanoma Dark-coloured malignant tumour of skin cells that produce the protective skin-darkening pigment melanin. , and Prostate cancer prostate cancer, cancer originating in the prostate gland. Prostate cancer is the leading malignancy in men in the United States and is second only to lung cancer as a cause of cancer death in men. . No other report will provide a likewise structure and analysis. The report not only provides a close to complete structure of each cancer indication field, it as well describes the progress of hundreds of drugs in development. Information on most company related activities are included. More than 250 companies are involved in developing new drugs within the top seven cancer indications. In the report the author does not only describe and analyze the latest years of progress but as we well provide an insight and framework to understand the complex field of cancer therapeutics therapeutics Treatment and care to combat disease or alleviate pain or injury. Its tools include drugs, surgery, radiation therapy, mechanical devices, diet, and psychiatry. . The report provides one of the most comprehensive coverage of the R&D trends to set the future marketplace. The author presents both an overview and a detailed description on the progress of key drugs in Phase II and III development, together with general descriptions on drugs and targets. In total we have selected more than 360 drug candidates to analyze. Among these drugs we clearly see substantial progress while others have failed. There will be a more intense competition in this market and current treatments will be changed for the benefit of more innovative therapies. Scope of this report: Progress analysis of Top 7 Cancer Indications, including players, drugs, clinical progress and pitfalls -Breast Cancer -Colon/colorectal cancer -Leukemia -Lung cancer -Lymphoma -Melanoma -Prostate Cancer Includes more than 250 drug developing companies Includes more than 360 candidate drugs The report includes more than 160 Tables, 200 Boxes and 600 high quality references Key reasons to read this report: - Understand the clinical and strategic challenges to the commercialization of drugs within the top 7 cancer indications - Assess opportunities and risks for the continued development of drugs in seven major cancer indications - Adopt knowledge from this analysis to drive strategic planning Strategic planning is an organization's process of defining its strategy, or direction, and making decisions on allocating its resources to pursue this strategy, including its capital and people. decisions in oncology oncology /on·col·o·gy/ (ong-kol´ah-je) the sum of knowledge regarding tumors; the study of tumors. on·col·o·gy n. drug development TOP 7 CANCER INDICATIONS THERAPEUTIC & COMPETITIVE INSIGHTS 1 EXECUTIVE SUMMARY 2 TABLE OF CONTENTS 21 LIST BOXES 22 LIST OF FIGURES 23 LIST TABLES 3 METHODOLOGY 4 LUNG CANCER 41 INTRODUCTION 42 CURRENT TREATMENT STRATEGIES 43 PROGRESS IN CURRENT TREATMENT STRATEGIES 44 KEY DRUG STRATEGIES IN LUNG CANCER 45 COMPETITIVE LANDSCAPE IN DRUG DEVELOPMENT: THE LATE STAGE PIPELINE 46 PROGRESS PROFILES ON APPROVED DRUGS In the United States, the FDA approves drugs. Before a drug can be prescribed, it must undergo an extensive FDA approval process. This process involves first testing the drug on animals or in medical labs. 5 COLON CANCER colon cancer, cancer of any part of the colon (often called the large intestine). Colon cancer is the second most common cancer diagnosed in the United States. 51 INTRODUCTION 52 CURRENT TREATMENT STRATEGIES 53 PROGRESS IN CURRENT TREATMENT STRATEGIES 54 KEY DRUG STRATEGIES IN CRC (Cyclical Redundancy Checking) An error checking technique used to ensure the accuracy of transmitting digital data. The transmitted messages are divided into predetermined lengths which, used as dividends, are divided by a fixed divisor. 55 COMPETITIVE LANDSCAPE IN CRC DRUG DEVELOPMENT 56 CURRENT CRC DRUG DEVELOPMENT 57 NECROTIC necrotic /ne·crot·ic/ (ne-krot´ik) pertaining to or characterized by necrosis. necrotic of or pertaining to cell death and enzymatic degradation. CELL DEATH INDUCERS 58 VACCINES: A HIGH THRESHOLD TO SUCCESS 59 IMMUNO-MODULATORS 510 ONCOLYTIC VIROTHERAPY IN CRC - A TEAM OF FOUR 6 PROSTATE CANCER 61 INTRODUCTION 62 CURRENT TREATMENT STRATEGIES 63 PROGRESS IN CURRENT TREATMENT STRATEGIES 64 KEY THERAPEUTIC STRATEGIES FOR FUTURE THERAPIES 65 COMPETITIVE LANDSCAPE IN DRUG DEVELOPMENT: THE LATE STAGE PIPELINE 66 CURRENT DRUG DEVELOPMENT: THE EARLY STAGE PIPELINE 7 BREAST CANCER 71 INTRODUCTION 72 PROGRESS IN CURRENT TREATMENT STRATEGIES 73 COMPETITIVE LANDSCAPE IN DRUG DEVELOPMENT: THE LATE STAGE PIPELINE 74 CURRENT DRUG DEVELOPMENT: THE EARLY STAGE PIPELINE 75 APPENDIX B NEAR TERM "BREAST CANCER" PROGRESS 8 MELANOMAS 81 INTRODUCTION 82 CURRENT TREATMENT STRATEGIES 83 PROGRESS IN CURRENT TREATMENT STRATEGIES 84 CYTOTOXIC DRUGS Cytotoxic drugs Drugs that function by destroying cells. Mentioned in: Antirheumatic Drugs 85 BIOLOGICAL TREATMENTS 86 COMPETITIVE LANSCAPE IN DRUG DEVELOPMENT: THE LATE STAGE PIPELINE 87 KEY THERAPY STRATEGIES 88 CURRENT DRUG DEVELOPMENT: THE EARLY STAGE PIPELINE 9 THE LYMPHOMAS 91 INTRODUCTION 92 CURRENT TREATMENT STRATEGIES 93 PROGRESS IN CURRENT TREATMENT STRATEGIES 94 KEY THERAPEUTIC STRATEGIES FOR FUTURE TREATMENTS 95 COMPETITIVE LANDSCAPE IN DRUG DEVELOPMENT: THE LATE STAGE PIPELINE 96 CURRENT DRUG DEVELOPMENT: THE EARLY STAGE PIPELINE 10 THE LEUKEMIAS 101 INTRODUCTION 102 CURRENT TREATMENT STRATEGIES 103 PROGRESS IN CURRENT TREATMENT STRATEGIES 104 KEY THERAPEUTIC STRATEGIES FOR FUTURE THERAPIES 105 COMPETITIVE LANDSCAPE IN DRUG DEVELOPMENT: THE LATE STAGE PIPELINE 106 CURRENT DRUG DEVELOPMENT: THE EARLY STAGE PIPELINE 107 DRUGS APPROVED FOR THE TREATMENT OF LEUKEMIA: A HISTORICAL PERSPECTIVE 11 DISCLAIMER 111 LIABILITY 112 COMPLETENESS 12 DRUG INDEX 13 COMPANY INDEX 21 List Boxes 22 List of Figures 23 List Tables Some of the Companies mentioned inside this report include: - Amgen - Chugai - Coley coley Noun Brit an edible fish with white or grey flesh [perhaps from coalfish] Pharmaceuticals - Cytokinetics - Genentech - GlaxoSmithKline - Hayashibara - Hoffmann La Roche La Roche may refer to:
- Novartis - OSI (1) (Open System Interconnection) An ISO standard for worldwide communications that defines a framework for implementing protocols in seven layers. Control is passed from one layer to the next, starting at the application layer in one station, proceeding to the - Pfizer - Roche - Sanofi-Aventis - Schering-Plough - Wyeth For more information visit http://www.researchandmarkets.com/reports/c50146 |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion